Insmed Inc (INSM)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $26.58B
Last updated: Nov 17, 2026 at 11:06 AM ET
Insmed Inc (INSM) Earnings: Report Dates and Results
Insmed (INSM) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Insmed reported EPS of -$0.46, below the -$0.34 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
INSM has an expected report date of Feb 17, 2027.
INSM Earnings Call
The latest INSM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, INSM beat 11, missed 27 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $524.43M, up 268.4% from $142.34M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.46 | -$0.34 | -$0.90 - -$0.09 | -35.29% | Miss | N/A | 18 | 0 up, 3 down | Oct 29, 2026 | $524.43M |
| Jun 30, 2026 | -$0.52 | -$0.69 | -$1.09 - -$0.05 | +24.64% | Beat | N/A | 16 | 3 up, 0 down | Aug 6, 2026 | $425.49M |
| Mar 31, 2026 | -$0.76 | -$1.00 | -$1.82 - -$0.68 | +24.00% | Beat | N/A | 13 | 2 up, 2 down | May 7, 2026 | $305.96M |
| Dec 31, 2025 | -$1.54 | -$1.17 | -$2.01 - -$0.67 | -31.62% | Miss | N/A | 13 | 8 up, 0 down | Feb 19, 2026 | $263.84M |
| Sep 30, 2025 | -$1.75 | -$1.37 | -$1.69 - -$1.23 | -27.74% | Miss | N/A | 13 | 2 up, 2 down | Oct 30, 2025 | $142.34M |
| Jun 30, 2025 | -$1.70 | -$1.30 | -$1.46 - -$1.18 | -30.77% | Miss | N/A | 13 | 3 up, 0 down | Aug 7, 2025 | $107.42M |
| Mar 31, 2025 | -$1.42 | -$1.20 | -$1.50 - -$1.01 | -18.33% | Miss | N/A | 12 | N/A | May 8, 2025 | $92.82M |
| Dec 31, 2024 | -$1.32 | -$1.23 | -$1.39 - -$1.03 | -7.32% | Miss | N/A | 9 | 4 up, 3 down | Feb 20, 2025 | $104.44M |
| Sep 30, 2024 | -$1.27 | -$1.22 | -$1.55 - -$1.06 | -4.10% | Miss | N/A | 15 | 0 up, 1 down | Oct 31, 2024 | $93.42M |
| Jun 30, 2024 | -$1.94 | -$1.23 | -$1.88 - -$0.50 | -57.72% | Miss | N/A | 14 | 1 up, 0 down | Aug 8, 2024 | $90.34M |
| Mar 31, 2024 | -$1.06 | -$1.20 | -$1.38 - -$1.11 | +11.67% | Beat | N/A | 15 | 2 up, 2 down | May 9, 2024 | $75.50M |
| Dec 31, 2023 | -$1.28 | -$1.13 | -$1.32 - -$0.95 | -13.27% | Miss | N/A | 12 | 1 up, 0 down | Feb 22, 2024 | $83.69M |
| Sep 30, 2023 | -$1.11 | -$1.11 | -$1.28 - -$0.90 | 0.00% | In line | N/A | 10 | 1 up, 0 down | Oct 26, 2023 | $79.07M |
| Jun 30, 2023 | -$1.78 | -$1.12 | -$1.24 - -$1.02 | -58.93% | Miss | N/A | 11 | 1 up, 0 down | Aug 3, 2023 | $77.23M |
| Mar 31, 2023 | -$1.17 | -$1.10 | -$1.26 - -$0.88 | -6.36% | Miss | N/A | 10 | 1 up, 1 down | May 4, 2023 | $65.21M |
| Dec 31, 2022 | -$1.21 | -$1.04 | -$1.13 - -$0.87 | -16.35% | Miss | N/A | 11 | 0 up, 2 down | Feb 23, 2023 | $59.30M |
| Sep 30, 2022 | -$1.09 | -$0.87 | -$0.92 - -$0.86 | -25.29% | Miss | N/A | 8 | 3 up, 0 down | Oct 27, 2022 | $67.73M |
| Jun 30, 2022 | -$0.80 | -$0.89 | -$0.95 - -$0.84 | +10.11% | Beat | N/A | 7 | 0 up, 0 down | Aug 4, 2022 | $65.22M |
| Mar 31, 2022 | -$0.80 | -$0.87 | -$0.98 - -$0.77 | +8.05% | Beat | N/A | 8 | 0 up, 0 down | May 5, 2022 | $53.11M |
| Dec 31, 2021 | -$0.95 | -$0.86 | -$1.00 - -$0.79 | -10.47% | Miss | N/A | 7 | 0 up, 0 down | Feb 17, 2022 | $56.12M |
| Sep 30, 2021 | -$0.96 | -$0.78 | -$0.89 - -$0.73 | -23.08% | Miss | N/A | 5 | N/A | Oct 28, 2021 | $46.76M |
| Jun 30, 2021 | -$0.91 | -$0.88 | -$0.95 - -$0.70 | -3.41% | Miss | N/A | 5 | N/A | Aug 5, 2021 | $45.37M |
| Mar 31, 2021 | -$0.89 | -$0.96 | -$1.12 - -$0.76 | +7.29% | Beat | N/A | 5 | N/A | May 6, 2021 | $40.21M |
| Dec 31, 2020 | -$1.00 | -$0.70 | -$0.79 - -$0.60 | -42.86% | Miss | N/A | 6 | N/A | Feb 25, 2021 | $41.41M |
| Sep 30, 2020 | -$0.63 | -$0.59 | -$0.71 - -$0.51 | -6.78% | Miss | N/A | 6 | N/A | Oct 29, 2020 | $43.64M |
| Jun 30, 2020 | -$0.64 | -$0.62 | -$0.77 - -$0.43 | -3.23% | Miss | N/A | 6 | N/A | Aug 6, 2020 | $42.49M |
| Mar 31, 2020 | -$0.74 | -$0.72 | -$0.89 - -$0.58 | -2.78% | Miss | N/A | 7 | N/A | Apr 30, 2020 | $36.86M |
| Dec 31, 2019 | -$0.59 | -$0.58 | -$0.66 - -$0.42 | -1.72% | Miss | N/A | 8 | N/A | Feb 25, 2020 | $45.71M |
| Sep 30, 2019 | -$0.68 | -$0.67 | -$0.75 - -$0.62 | -1.49% | Miss | N/A | 8 | N/A | Oct 30, 2019 | $38.88M |
| Jun 30, 2019 | -$0.81 | -$0.86 | -$0.95 - -$0.56 | +5.81% | Beat | N/A | 9 | N/A | Aug 1, 2019 | $29.97M |
| Mar 31, 2019 | -$0.96 | -$1.00 | -$1.17 - -$0.83 | +4.00% | Beat | N/A | 9 | N/A | May 7, 2019 | $21.90M |
| Dec 31, 2018 | -$1.19 | -$1.05 | -$1.16 - -$0.93 | -13.33% | Miss | N/A | 10 | N/A | Feb 22, 2019 | $9.84M |
| Sep 30, 2018 | -$1.14 | -$1.06 | -$1.16 - -$0.97 | -7.55% | Miss | N/A | 10 | N/A | Oct 30, 2018 | N/A |
| Jun 30, 2018 | -$1.00 | -$1.06 | -$1.38 - -$0.92 | +5.66% | Beat | N/A | 10 | N/A | Aug 2, 2018 | N/A |
| Mar 31, 2018 | -$0.87 | -$0.96 | -$1.82 - -$0.26 | +9.38% | Beat | N/A | 9 | N/A | May 2, 2018 | N/A |
| Dec 31, 2017 | -$0.85 | -$0.64 | -$0.76 - -$0.46 | -32.81% | Miss | N/A | 9 | N/A | Feb 23, 2018 | N/A |
| Sep 30, 2017 | -$0.69 | -$0.70 | -$0.74 - -$0.60 | +1.43% | Beat | N/A | 7 | N/A | Nov 2, 2017 | N/A |
| Jun 30, 2017 | -$0.72 | -$0.63 | -$0.66 - -$0.61 | -14.29% | Miss | N/A | 7 | N/A | Aug 3, 2017 | N/A |
| Mar 31, 2017 | -$0.60 | -$0.60 | N/A | 0.00% | In line | N/A | N/A | N/A | May 3, 2017 | N/A |
| Dec 31, 2016 | -$1.10 | -$0.89 | N/A | -23.60% | Miss | N/A | N/A | N/A | Feb 23, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$6.41, after -$5.59 the year before. It was -$2.84 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$6.41 | N/A |
| Dec 31, 2024 | -$5.59 | N/A |
| Dec 31, 2023 | -$5.34 | N/A |
| Dec 31, 2022 | -$3.90 | N/A |
| Dec 31, 2021 | -$3.71 | N/A |
| Dec 31, 2020 | -$3.01 | N/A |
| Dec 31, 2019 | -$3.04 | N/A |
| Dec 31, 2018 | -$4.20 | N/A |
| Dec 31, 2017 | -$2.86 | N/A |
| Dec 31, 2016 | -$2.84 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,500 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 9,523 | 14 | |
| 2026Q2 | Jun 30, 2026 | 8,179 | 21 | |
| 2026Q1 | Mar 31, 2026 | 12,112 | 22 | |
| 2025Q4 | Dec 31, 2025 | 6,402 | 5 | |
| 2025Q3 | Sep 30, 2025 | 10,247 | 23 | |
| 2025Q2 | Jun 30, 2025 | 8,540 | 17 | |
| 2025Q1 | Mar 31, 2025 | 10,441 | 19 | |
| 2024Q4 | Dec 31, 2024 | 11,255 | 19 |
2026Q3 Earnings Call
Opening remarks
Will Lewis Chair and Chief Executive Officer Good morning. Today's updates are intended to illustrate three overarching ideas. The first is that Insmed has evolved into a diversified biotechnology company that we believe can generate significant revenue and earnings with substantial growth over the next 10 years and beyond. In addition to exceeding $1 billion in total company revenue year to date, I am pleased to announce that BRINSUPRI has already achieved blockbuster status, having generated more than $1 billion in revenue in its first four full quarters of launch. We believe we have only scratched the surface of the potential addressable patients who may benefit from this first-ever approved foundational medicine in bronchiectasis. While we have treated tens of thousands of patients in the first year, there remain hundreds of thousands of patients already diagnosed and waiting, with potentially millions more who may benefit. We have literally only just begun to see the benefit BRINSUPRI will bring to patients, and this has been achieved while continuing to deliver for patients with NTM with ARIKAYCE. As a result of this performance, we are raising our full year 2026 guidance for both products. I am very proud of the work we have done, but there is always more we can improve upon. I continue to believe the growth road ahead for our medicines is very substantial. Looking ahead, we have forecasted our three lead respiratory assets to collectively grow at a compound annual growth rate of more than 20% over the next 10 plus years. In doing so, we expect our three lead respiratory assets to collectively exceed $14 billion in estimated peak sales, with room for potential upside. BRINSUPRI's peak sales estimate of more than $7 billion does not include the COPD and asthma comorbid patient populations, which we estimate number in the low single-digit millions of additional patients. We believe the future impact of BRINSUPRI on these additional patients, who are on max dose treatments for their conditions but are still suffering damage from exacerbations, could be significant. The consequent revenue generation from success in treating these patients could represent potentially as much as, or even more than, the current $7 billion peak sales estimate. In a moment, I will speak to the initiatives we are deploying to tackle this important opportunity. TPIP is also expected to be a massive product, potentially hitting the market by the end of this decade with a peak sales estimate of more than $6 billion from four separate indications. Thus far, TPIP has distinguished itself within the prostanoid class with superior improvement in six-minute walk distance and PVR reduction, among other efficacy measures, as well as better safety and convenience with its clearly differentiated profile.
Frequently Asked Questions About INSM
When is Insmed's next earnings date?
Insmed's next earnings report is expected for Feb 17, 2027.
Did INSM beat earnings estimates last quarter?
No. Insmed reported EPS of -$0.46 for the quarter ended Sep 30, 2026, below the -$0.34 estimate by 35.29%.
What EPS do analysts expect from INSM next quarter?
The consensus EPS estimate for Insmed for the quarter ending Dec 31, 2026 is -$0.33 from 25 analysts, with estimates from -$1.12 to -$0.02.
How often does INSM beat earnings estimates?
Insmed beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -12.80%.
INSM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts